Innate Immunotherapeutics LimitedINMMF
A clinical-stage biopharmaceutical company developing therapies for serious diseases, including multiple sclerosis and other autoimmune conditions. Its lead product candidate, MIS416, has completed Phase 2b trials, and the company has attracted attention from high-profile investors, including former U.S. Representative Tom Price. Investors track INMMF for its potential in the immunotherapy space and its historical association with political figures.
Congressional Interest in Innate Immunotherapeutics Limited (INMMF)
1 member of Congress has disclosed 1 trade in Innate Immunotherapeutics Limited (INMMF), a Healthcare company. The buy/sell breakdown shows 1 purchase versus 0 sales, indicating net buying interest from lawmakers. All data is sourced from STOCK Act periodic transaction reports filed with Congress.
Who in Congress Is Trading INMMF?
| Date | Politician | Type | Amount |
|---|---|---|---|
| 2015-02-05 | Chris Collins | buy | $1M-$5M |